Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 16, 2025 | Ambros Therapeutics | $125.0M Series A | Trit Garg, Matthew Hammond | Massimo Di Martino, Adage Capital Management, Arkin Bio Ventures, Balyasny Asset Management, Janus Henderson Investors |
| May 16, 2022 | Kriya Therapeutics | $270.0M Series C | Jim Momtazee | Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT |
| Jul 14, 2021 | Kriya Therapeutics | $100.0M Series B | Jim Momtazee | Alumni Ventures, Amplo, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, Hongkou, JDRF, Narya Capital, QVT, Woodline Partners |